Health Trials

Relapsed and Refractory

3

Review clinical trials related to Relapsed and Refractory. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) for treating recurrent and refractory DLBCL masses. It seeks to establish a novel local salvage treatment strategy for such patients while providing preliminary theoretical foundations and clinical data to support future large-scale, multicenter clinical trials.

Participants needed: 10
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Ting YANGUpdated: Nov 18, 2025Locations: 1
Eligibility criteria

Platelet count ≥ 30 × 10^9/L; [+4]

(1) Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or o...

Read more
Status: Recruiting

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients

Participants needed: 22
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Xiamen UniversityUpdated: Jul 23, 2025Locations: 1
Eligibility criteria

Written informed consent must be obtained before any trial-related procedures ar... [+8]

B-cell non-Hodgkin's lymphoma with loss of CD20 expression. [+19]

Read more
Status: Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

Participants needed: 100
Trial details
Phase: Early Phase 1Age: 3-70Biological sex: AllType: InterventionalSponsor: He HuangUpdated: Aug 21, 2020Locations: 1
Eligibility criteria

Male or female aged ≥ 3 and <70 years old; [+20]

patients with extramedullary lesions, except those with CNSL (CNS-1) under effec... [+25]

Read more